SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Oct. 19, 2017	Oct. 31, 2015	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share			$ 0.001	$ 0.001
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			73,800,491		78,142,133
Goods [Member]
Significant Accounting Policies [Line Items]
Revenues			$ 4,553		$ 2,889
Maximum [Member]
Significant Accounting Policies [Line Items]
Additional AmountPayable For Achievement Of Regulatory And Commercial Milestones	$ 320,000
Brazil [Member]
Significant Accounting Policies [Line Items]
Percentage Of Adult Gaucher Patients Treated With alfataliglicerase			10.00%
Brazil [Member] | Goods [Member]
Significant Accounting Policies [Line Items]
Revenues			$ 2,573		$ 1,243
Brazil Agreement [Member]
Significant Accounting Policies [Line Items]
Supply Commitment In Year 2017				$ 24,300
Pfizer Agreement [Member]
Significant Accounting Policies [Line Items]
Proceeds From Exchange For Rights To Royalties		$ 36,000
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues and Expenses Sharing Percentage		100.00%
Chiesi Agreement [Member]
Significant Accounting Policies [Line Items]
Upfront Nonrefundable Noncreditable Payment Receivable	25,000
Additional Amounts Payable To Cover Development Costs	25,000
Maximum Entitlement Of Development Costs To Cover Per Year	$ 10,000
Revenues				$ 1,800
Chiesi Agreement [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage	15.00%
Chiesi Agreement [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage	35.00%